BR Biopharma, Inc. (NASDAQ:BRBI – Get Free Report) rose 0.4% on Thursday . The company traded as high as $11.29 and last traded at $11.3360. 266 shares were traded during trading, a decline of 65% from the average session volume of 769 shares. The stock had previously closed at $11.29.
Analysts Set New Price Targets
Separately, Weiss Ratings raised BR Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.
Check Out Our Latest Report on BRBI
BR Biopharma Stock Performance
BR Biopharma (NASDAQ:BRBI – Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.09 earnings per share for the quarter. The business had revenue of $25.95 million during the quarter.
BR Biopharma Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 5th. Stockholders of record on Tuesday, May 19th were issued a $0.147 dividend. The ex-dividend date was Tuesday, May 19th. This represents a $0.59 annualized dividend and a dividend yield of 5.2%.
Institutional Investors Weigh In On BR Biopharma
A hedge fund recently bought a new position in BR Biopharma stock. Acuitas Investments LLC purchased a new position in shares of BR Biopharma, Inc. (NASDAQ:BRBI – Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,000 shares of the company’s stock, valued at approximately $45,000. BR Biopharma comprises approximately 3.2% of Acuitas Investments LLC’s portfolio, making the stock its 7th biggest holding.
About BR Biopharma
BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.
See Also
- Five stocks we like better than BR Biopharma
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for BR Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BR Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
